Cancer is basically uncontrollable growth of abnormal cells; which invades normal functioning of human bodies. In cancer, at metastasis stage, some advance malignant cells; known as circulated tumor cells (CTCs) get released into the blood stream along with lymphatic system and disseminated. At exactly this stage, liquid biopsy is done with minimal invasion upon non-accessible cells, which has become a much-preferred choice than solid tumor biopsy in recent time. On-invasive diagnostic testing methods have initiated the use of precision medicines in a large way in the field of oncologic treatments specifically.
Presently, liquid biopsies are widely used in monitoring and diagnosing many dreadful diseases along with cancer; giving an opportunity to patients for better clinical care. In this context, circulating tumor DNAs have already shown their potential as ‘Biomarkers’ in malignancy detection process at an early stage and helping the oncologists in correct prognosis of patients suffering at metastasis stage of cancer. This whole detection process is indirectly driving the CTC diagnostic market at a significant rate with immense possibilities.
The prime reason for the progress of circulating tumors diagnostics market is the rising number of patients suffering from carcinogenic disease; second major cause of global death (WHO data, 2012). Here, prime factor for this devastating, lethal disease is considered as lifestyle changes, exorbitant pollution level, smoking, genetic changes and obesity.
In this context, circulating tumor cells are playing a great role by acting as ‘biomarkers’ in the field of diagnostic imaging technology. Technological advancement for proliferation of CTC cells at molecular level can be considered another prime factor bolstering the growth of CTC diagnostics market worldwide. A hike in geriatric population worldwide is also set to positively influence the growth of this market, as CTC technique has huge potential for monitoring cancer at a faster pace.
However, high cost of these advanced diagnostic techniques and self-imbibed inhibitions for adopting specific interventions can hinder the growth of the market during the forecast period.
The circulating tumor cell diagnostics market has been segregated based on, technology, application, end-user and regional demand. The technology segment includes CTC enrichment, CTC detection and CTC analysis. The CTC enrichment section can be sub segmented into microchips, single spiral micro channel, positive (both in-vivo and ex-vivo types) and negative selection; on the other hand, CTC detection procedure consists of molecular-based (RNA) technologies, optical-based flow cytometry, EPISPOT in-vitro cell culture, in-vitro cell invasion assay and different xeno transplantation models.
Based on application, the circulating tumor cell diagnostics market can be classified into different kinds of cancer viz. breast cancer, lung cancer, colorectal cancer, prostate cancer and others (skin cancer, pancreatic cancer and ovarian cancer).
End-User segment includes biotechnological research centers, hospitals &clinics, pharmaceuticals and academic research institutions. Here, hospitals & clinics segment is holding the dominance owing to the easy reimbursement payments and more number of patient’s footfall.
By geography, the circulating tumor cell (CTC) diagnostics market has been divided into regions such as North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America is expected to be the dominating market among all regions. Increasing geriatric population, huge number of research in this field along with the presence of major biotechnology based companies and rising incidences of carcinogenic diseases in the country are the major reasons for the country’s dominance in this market. Europe is another significant circulating tumor cell (CTC) diagnostics market considering the presence of technological advancement, government support in R&D for more invention in molecular diagnostics and high per capita income. In terms of growth rate, Asia Pacific is expected to witness the highest CAGR among all regions. There have been immense technological advancements in the healthcare care sectors of China, India and Japan among other countries of Asia Pacific. China and India are the most populated countries in the world. A significant proportion of the populations of both the countries are suffering from lethal diseases, ready for opting those CTC diagnostic measures; owing to rising health concern.
Some of the major players in the circulating tumor cell (CTC) diagnostics market are Advanced Cell Diagnostics, AVIVA Biosciences Corp., Biocept, Inc., Celula, Inc., Epic Sciences, Inc., Fluxion Biosciences Inc., Rare Cells USA, STEM CELL Technologies, Veridex LLC and Vitatex Inc. among others.
Circulatory Tumor Cell (CTC) Diagnostics Market: By Technology
Circulatory Tumor Cell (CTC) Diagnostics Market: By Application
Circulatory Tumor Cell (CTC) Diagnostics Market: By End-User
Circulatory Tumor Cell (CTC) Diagnostics Market: By Geography